QURENasdaqPharmaceutical PreparationsFiscal year ends December 31

uniQure N.V.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$22.20+0.42 (+1.93%)

Close on Oct 19, 2026

Market cap: $1.47B
P/E (TTM): –
Dividend yield: –

uniQure N.V. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	16	27	16	106	524	38	7.28	11	13	25	11	6.14
Cost of Revenue	1.69	1.27	0.07	1.25	25	2.90	1.65	1.20	0.82	1.35	–	–
Gross Profit	14	26	16	105	499	35	5.63	10	12	24	–	–
Research & Development	141	144	215	198	144	122	95	75	72	73	59	44
Selling, General & Admin	65	53	75	55	56	43	34	25	25	26	23	17
Operating Expenses	–	–	–	–	–	–	–	100	97	99	83	61
Total Costs & Expenses	208	215	303	256	225	165	128	100	97	–	–	–
Operating Income	-185	-184	-283	-143	311	-125	-121	-88	-71	-72	-71	-54
Interest Expense	62	64	42	12	7.47	3.83	3.81	2.16	2.23	2.17	2.57	2.02
Interest & Investment Income	17	21	20	0.61	0.16	0.94	3.55	2.73	0.12	0.07	0.12	0.22
Other Non-Operating Income	11	–	–	2.76	-0.16	0.48	-2.53	0.21	-2.44	0.79	-7.16	0.02
Merger & Restructuring Charges	–	–	2.55	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	1.44	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	1.15	–	–	–	–	–	–	–	–	–	–
Pretax Income	-193	-237	-307	-128	333	-141	-124	-83	-79	-72	-83	-50
Income Tax Expense	5.63	2.43	1.92	-1.47	3.22	-16	–	0.23	-0.20	1.15	-1.18	-0.54
Net Income incl. Noncontrolling Interests	-199	-240	-308	-127	330	-125	-124	-83	-79	-73	-82	–
Net Income	-199	-240	-308	–	–	–	–	–	–	–	–	–
Net Income to Common	-199	-240	-308	-127	330	-125	-124	-83	-79	-73	-82	-50
EPS (Basic)(per share)	-3.46	-4.92	-6.47	-2.71	7.17	-2.81	-3.11	-2,340.00	-2,940.00	-2.93	-3.72	-2.91
EPS (Diluted)(per share)	-3.46	-4.92	-6.47	-2.71	7.04	-2.81	-3.11	-2,340.00	-2,940.00	-2.93	-3.72	-2.91
Shares Outstanding (Basic, Weighted)(shares)	58	49	48	47	46	44	40	36	27	25	22	17
Shares Outstanding (Diluted, Weighted)(shares)	58	49	48	47	47	44	40	36	27	25	22	17
EBITDA	-171	-172	-271	-135	318	-115	-114	-76	-64	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 92.5%
Operating margin: -1071.5%
Net margin: -1350.7%
Return on equity, FY2025: -207.1%

Financial strength

Current ratio: 10.01
Debt to equity: 0.15
Debt to assets: 5.1%
Cash to current liabilities: 495.6%

Valuation

P/E ratio: –
Price to sales: 78.76
Price to book: 4.54
Dividend yield: –